Dermatitis Latest News Archive
The presence of atopic dermatitis in both children and adults was associated with significantly higher odds for the development of ear infection, urinary tract infection, and strep throat.
Topical application of a transient receptor potential vanilloid subfamily, member 1 (TRPV1) antagonist may be an effective and safe treatment for patients with mild-to-moderate atopic dermatitis.
Pooling data from 11 of 14 relevant studies, patients with atopic dermatitis were 44% more likely to experience suicidal ideation compared with participants without atopic dermatitis.
The investigators sought to explore heritable, environmental, and clinical factors linked to persistent atopic dermatitis based on 13 years of follow-up in an at-risk birth cohort.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.
Investigators examined whether excessive food allergy testing in patients with atopic dermatitis might lead to food intolerance when certain foods are removed from the diet.
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
The prevalence of atopic dermatitis is 7.3 percent among U.S. adults, and patients with atopic dermatitis and more severe disease have worse quality of life.
Investigators sought to characterize phenotypic variations in patients with atopic dermatitis who were African American and European American.
Dupilumab reduced cutaneous and systemic measures of inflammation and improved disease-severity scores in 4 weeks in moderate to severe atopic dermatitis.
Few available studies investigated the risk of completed suicide; however, most of these found a positive correlation between AD and completed suicide.
Variation of Staphylococcus aureus Clonal Complex Type Linked to Worse Disease Activity in Atopic Dermatitis
Of patients who were colonized at both visits, 51.9% remained colonized with the same CC-type at follow-up.
The use of bee venom and its major component, melittin, has proven suitable as an epicutaneous application for the treatment of atopic dermatitis.
An immunoglobulin E (IgE) antibody response to Staphylococcus aureus superantigens is more common among individuals with atopic dermatitis than healthy controls.
The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.
The study findings support the heavy burden that atopic dermatitis places on patients, particularly those with moderate and severe disease.
Some aspects of pathophysiologic mechanisms may differ in children with atopic dermatitis with light skin types vs those with dark skin types.
Dupilumab therapy provided an additional 1.91 quality-adjusted life years during the remaining lifetime of a patient compared with usual care.
Nemolizumab Effective for Moderate, Severe Atopic Dermatitis Inadequately Controlled With Topical Therapy
For patients with moderate to severe atopic dermatitis inadequately controlled with topical therapies, the anti-IL-31 receptor A humanized monoclonal antibody nemolizumab may provide benefit.
The investigators sought to explore the association of atopic dermatitis with subsequent cataract development and cataract surgery in a Korean pediatric population.
The investigators sought to explore adolescents' experiences with, preferences for, and beliefs about their atopic dermatitis treatment.
Patients with moderate/severe atopic dermatitis have higher patient-reported burden than those with mild atopic dermatitis, regardless of disease control.
The investigators sought to determine the prevalence of, risk factors associated with, and cost of ED care among patients with atopic dermatitis or eczema in the United States by analyzing a 20% sample of ED visits throughout the country.
The investigators sought to explore whether adults with atopic eczema are at a higher risk for cardiovascular disease, and whether the risk varies based on severity of the disease and the activity of the condition over time.
Patients with atopic dermatitis should be encouraged to increase their level of physical activity, partake in adequate weight-bearing exercises, and have a sufficient intake of calcium and vitamin D.
In AD, associations between AD healthcare utilization and hours of cloud cover were generally positive, whereas hours of bright sunlight were generally inversely associated with health care utilization.
This finding could lead to the development of a low-cost atopic dermatitis therapy that does not require daily application.
Researchers examined the clinical effectiveness and cost-effectiveness of emollient bath additives in the management of childhood eczema.
Patients with difficult-to-treat AD often experience concomitant, multiple contact allergies, which may be why their AD actually becomes a difficult-to-treat disease.
In patients with atopic dermatitis and birch pollen allergy, consumption of birch pollen-related foods is associated with allergic reactions and deterioration of AD.
When testing for sensitivity to histamine, larger swelling sizes were recorded for infants with eczema and atopic dermatitis compared with infants without those conditions.
Harmony Herbal announced the launch of Skin Therapy Calm over-the-counter (OTC) topical and Calm + Detox supplement duo for the symptomatic relief of rash, eczema, and dermatitis.
Researchers hypothesized that the age of asthma onset in children with early-onset eczema would be younger compared with children with asthma and no eczema.
A recent study showed that the administration of dupilumab was associated with comparable/significant improvement in signs and symptoms of atopic dermatitis in patients with or without comorbid asthma.
The proportion of participants in the treatment groups who achieved EASI-50 was statistically significant compared with placebo as early as 4 weeks after beginning treatment.
Researchers compared the efficacy of moisturizer containing 4-t-butylcyclohexanol and licochalcone A to 0.02% triamcinolone acetonide (TA) for treating facial dermatitis.
Despite not reaching significance in the total population, the progressive clinical improvements seen in patients with severe AD suggest a therapeutic advantage.
Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria.
Twice-daily use of topical corticosteroids in all treatment arms, both prior to and during the study, impaired participants' ability to fully assess the efficacy of lebrikizumab.
Methotrexate and azathioprine appear to be effective and safe as maintenance treatments in moderate-to-severe atopic dermatitis for up to 5 years.
Researchers advise dermatologists to discuss the importance of skin examinations and sunscreen use with patients with atopic dermatitis, who are an an increased risk of squamous cell carcinoma.
For patients with chronic palmar hand eczema, both psoralen ultraviolet A and narrowband ultraviolet B treatment improve the severity of the disease.
Despite an increased prevalence, researchers found no significant evidence indicating atopic dermatitis as an independent risk factor for cardiometabolic disease.
Dupilumab Plus Concomitant Topical Corticosteroids Effective for Treatment-Refractory Atopic Dermatitis
Patients with treatment-refractory atopic dermatitis may have good response to dupilumab plus concomitant topical corticosteroids.
In young children, atopic dermatitis severity is linked to an immunoglobulin response directed against Staphylococcus aureus antigens with mainly immune-modulatory functions.
Chronic Spontaneous Urticaria Disease Activity, Treatment Response Linked to C-Reactive Protein Levels
C-reactive protein levels are frequently elevated in patients with chronic spontaneous urticaria, and these elevations are relevant and potentially useful in management of the condition.
Inadequately controlled patients had worse disease-specific quality of life, higher level of work impairment, greater itch, and more sleep interference with daily living.
Prolonged and exclusive breastfeeding may reduce the risk of flexural dermatitis in adolescence, but does not affect lung function or questionnaire-derived measures of asthma or atopic eczema.
Clinical studies have demonstrated an association between S aureus and the pathogenesis of AE, with affected persons typically prone to colonization.
Systemic corticosteroid medications tend to be overprescribed for patients with atopic dermatitis, and the International Eczema Council released a consensus statement on when they should be prescribed.
A new class of biologic medications was found to improve clinical signs and symptoms of moderate-to-severe atopic dermatitis.
Although pediatric chronic urticaria is associated with a low rate of resolution, new research suggests the presence of certain biomarkers may help in predicting disease resolution.
Products that contain benzalkonium chloride, a commonly used preservative in various personal care products, should be utilized with caution in patients with compromised skin barriers.
Crisaborole ointment was found to be a safe treatment of mild to moderate atopic dermatitis with a low frequency of treatment-related adverse effects.
Supplementing high-risk infants with probiotics does not help prevent future eczema or asthma development, new research suggests.
Identification of specific antigens via IgE quantitative assaying of allergies can guide patients with atopic dermatitis to make lifestyle changes to improve outcomes.
Seborrheic dermatitis is a common inflammatory condition in middle-aged and elderly individuals, particularly in males and those with darker skin.
Dermatology Advisor Articles
- Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies
- Strong Bidirectional Association Found Between Depression and Alopecia
- Immunosuppressants Associated With Unsatisfactory Outcomes in Atopic Dermatitis
- Molecular Profiles Vary With Age in Atopic Dermatitis
- Johnson & Johnson to Provide Drug Prices in TV Ads
- Aesthetic-Only Neurotoxin Jeuveau Gets FDA Approval
- Turmeric Polyherbal Supplement May Help Reduce Facial Erythema
- Dupilumab Impacts Symptoms of Atopic Dermatitis in Real-Life Setting
- HIDRAdisk Is a Validated Visual Tool to Assess Hidradenitis Suppurativa Burden
- Thermography Helps Diagnose Allergic vs Irritant Contact Dermatitis